Aspen and Bambusa Launch US IPOs
Drug developers Aspen Neuroscience and Bambusa Therapeutics launched their initial public offerings in the United States. Both companies are marketing shares to fund clinical trials for their respective therapeutic candidates.
Xurve View
Insights:
Xurve View
Aspen Neuroscience and Bambusa Therapeutics launched their United States IPO roadshows on Monday morning, targeting a combined share offering of 18.76 million shares.
The biotechnology sector continues to drive new listings in New York this autumn, offsetting a broader slowdown across other industries. Over half a dozen biotech firms have launched public offerings in the United States since September, fueled by investor demand for clinical catalysts.
